# Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer

> **NCT00268593** · PHASE2 · COMPLETED · sponsor: **Progen Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** PI-88
- **DRUG:** docetaxel
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00268593
- **Lead sponsor:** Progen Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268593, "Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00268593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*